Crism Therapeutics has successfully treated its first patient, a significant milestone marking the start of Phase 2 clinical data generation for its lead oncology asset. In May 2026, £2.5m was raised at 10p with warrants at 15p, which was followed by grant funding of c. £1m to support this Phase 2 development. This is an open-label clinical trial for glioblastoma, one of the most challenging and underserved areas of oncology, where no effective standard of care remains for recurrent disease. The funds were also directed towards the development of docetaxel-ChemoSeed for prostate cancer. The ...
© UK Investor Group UK Investor and UK Investor Magazine are registered trademarks of UK Investor Group Ltd (09932115) | All rights reserved
